Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupBrain Tumors (ped.)Neuro-OncologyDiseaseGliomaSubgroupWHO grade 1 and 2ICD10C71.-MeSHAstrocytomaGliomaSequenceChemotherapyChemo-substanceLomustineProcarbazineTioguaninVincristineChemo-substanceLomustineProcarbazineTioguaninVincristineChemo-substanceLomustineProcarbazineTioguaninVincristineChemo-substanceLomustineProcarbazineTioguaninVincristineNo. Substances4 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances4Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Increase AminotransferasesNeutropeniaSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorAter JLDiseaseProgressives oder residuelles Low-Grade Gliom bei Kindern, WHO Grad 1+ 2, Alter unter 10, ErstlinieOriginUniversity of Texas MD Anderson Cancer Center, Houston, COG StudieProtocols in Revision 1 protocol foundProtocols under revision.Tioguanin 30 / Procarbazine 50 / Lomustine 110 / Vincristine 1.5, Glioma (PID604 V1.1)
